BURLINGTON, MA — August 17, 2026 — Chrysalis Services, LLC today announced the launch of the Chrysalis Platform, a new framework that provides risk mitigation and accelerated access to the GMP infrastructure, systems, and expertise that biopharma innovators need to advance through each stage of development and manufacturing. The company also announced Plakous Therapeutics as its first partner on the platform.
Structured around four connected programs, Chrysalis PILOT™, Chrysalis ONE™, Chrysalis ADVANCE™, and Chrysalis LAUNCH™, the platform is designed to give biopharma companies the GMP infrastructure, systems, and expertise they need at each stage of development without the burden of building or traditional outsourcing.
“Each Chrysalis program is designed to provide established, operational GMP infrastructure and expertise that is both fit for purpose and fit for phase,” said Sarah Stevens, CEO of Chrysalis. “Each program uniquely reduces risk, time, and cost of GMP manufacturing while ensuring accelerated access and full control of product and process for those that need it, when they need it.”
Innovation rarely follows a straight line, and companies can enter the Chrysalis Platform at any stage of development. Because each program is designed to build on work already completed, innovators don’t need to start over as their needs evolve. Instead, key deliverables, infrastructure, quality systems, GMP readiness, and operational knowledge carry forward as programs advance.
Platform partners have access to operational GMP infrastructure including cleanroom hosting, controlled storage, warehousing, environmental monitoring, streamlined facility operations, and QA services across all Chrysalis locations. Partners can also plug into a hybrid Quality Management System instead of building one from scratch, and can draw on manufacturing readiness and CMC strategy support including risk assessments, GMP gap analyses, tech transfer planning, IND/NDA readiness, and validation roadmaps. Regulatory support spans IND/NDA planning, FDA meeting and BLA preparation, CMC document review, and inspection readiness. Through the Chrysalis Platform and network, partners gain access to process development and process optimization expertise, analytical and microbial testing, and bespoke consulting.
Plakous Therapeutics joins the platform as its first partner pursuing novel approaches to complex therapeutic challenges. “Access to established, operational GMP infrastructure at the right stage of development is a real challenge for companies advancing novel biologics,” said Robert Boyce, CEO of Plakous Therapeutics. “Partnering with Chrysalis provides us the infrastructure, systems, and expertise we need to advance our therapy toward the clinic and ultimately commercialization with full control of our outcomes and milestones.”
The Chrysalis Platform is available now, and companies interested in learning more can visit chrysalisgxp.com/our-platform or email info@chrysalisgxp.com.
About Plakous Therapeutics
Plakous Therapeutics is a regenerative medicine company developing novel biologics to address critical unmet needs in neonatal diseases. The company’s lead asset, HPE, is a first‑in‑class biologic designed to modulate inflammation and support tissue repair. Plakous is advancing HPE to prevent necrotizing enterocolitis (NEC) in extremely premature infants, one of the most devastating conditions in neonatal care. The company is headquartered in Winston‑Salem, North Carolina. plakoustherapeutics.com
About Chrysalis
Chrysalis provides integrated GMP infrastructure, operational support, and flexible facility solutions for biopharmaceutical companies. Through its facilities in Massachusetts and North Carolina, Chrysalis helps organizations accelerate development and manufacturing activities while preserving capital and maintaining operational control.
Media Contact
Casey Gillan
Director of Marketing
casey.gillan@chrysalisgxp.com
Make it yours
Choose your equipment, choose your layout, choose your services. Make yourself at home in a space designed for you.
